{
    "clinical_study": {
        "@rank": "92526", 
        "arm_group": [
            {
                "arm_group_label": "Dexanabinol", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of dexanabinol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single oral dose of matching placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety and observe the pharmacokinetics\n      (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy\n      male subjects following a single oral dose."
        }, 
        "brief_title": "Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics", 
            "Cancer"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males aged 18 to 45 years\n\n          -  Body mass index 18.0 to 32.0 kg/m2, or if outside the range, considered not\n             clinically significant by the investigator\n\n        Exclusion Criteria:\n\n          -  Participation in a clinical research study within the previous 3 months\n\n          -  Current smokers and those who have smoked within the last 12 months\n\n          -  History of any drug or alcohol abuse in the past 2 years"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054754", 
            "org_study_id": "ETS2101-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dexanabinol", 
                "description": "Oral formulation of dexanabinol", 
                "intervention_name": "Dexanabinol", 
                "intervention_type": "Drug", 
                "other_name": "ETS2101"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HU 211", 
                "Tetrahydrocannabinol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dexanabinol", 
            "Oral", 
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "state": "Nottinghamshire", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Quotient Clinical"
            }, 
            "investigator": {
                "last_name": "Philip Evans, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects", 
        "other_outcome": {
            "description": "Blood samples taken and analysed for the purposes of the identification and quantification of pharmacodynamic biomarkers pre-dose and at several points after dosing.", 
            "measure": "Pharmacodynamic biomarker assessment", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose, 1, 6 and 24 hours post dose"
        }, 
        "overall_contact": {
            "last_name": "Philip Evans, MD", 
            "phone": "+44 115 974 9000"
        }, 
        "overall_official": {
            "affiliation": "Quotient Clinical", 
            "last_name": "Philip Evans, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety and tolerability based on the number of participants with adverse events. Assessment and comparison to baseline of the following:\nPhysical exam\nSafety bloods and urinalysis\n12-lead ECG\nVital signs", 
            "measure": "Safety and tolerability based on the number of participants with adverse events and comparison of baseline and post dose parameters", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed until follow up visit, 6-11 days after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacokinetic parameters will be assessed in a blinded fashion at the end of each cohort, prior to dose escalation.", 
            "measure": "Pharmacokinetics: Area under curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose, 0.5,1,1.5,2,3,4,5,6,8,10,12,16,24,36,48 hours post dose"
        }, 
        "source": "e-Therapeutics PLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "e-Therapeutics PLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}